These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3875156)

  • 1. Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor.
    Balch CM; Itoh K; Tilden AB
    Surgery; 1985 Aug; 98(2):151-7. PubMed ID: 3875156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells.
    Itoh K; Tilden AB; Balch CM
    Cancer Res; 1985 Jul; 45(7):3173-8. PubMed ID: 3924397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.
    Sondel PM; Hank JA; Kohler PC; Chen BP; Minkoff DZ; Molenda JA
    J Immunol; 1986 Jul; 137(2):502-11. PubMed ID: 2424971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
    Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
    Itoh K; Pellis NR; Balch CM
    Cancer Immunol Immunother; 1989; 29(1):57-62. PubMed ID: 2785000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
    Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
    Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of serum immunosuppressive factors on the cytotoxicity of lymphokine-activated killer (LAK) cells induced by recombinant interleukin 2(R-IL2)].
    Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Kunii Y; Sakata K
    Nihon Geka Gakkai Zasshi; 1988 Jul; 89(7):992-8. PubMed ID: 2975748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma.
    Munn DH; Cheung NK
    Cancer Res; 1987 Dec; 47(24 Pt 1):6600-5. PubMed ID: 3499978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
    Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Belli F; Sciorelli G; Ravagnani F; Galazka AR; Cascinelli N; Parmiani G
    Cancer Res; 1989 Sep; 49(18):5230-4. PubMed ID: 2788498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of human recombinant interleukin-2 on cytotoxic response of peripheral blood mononuclear cells in melanoma patients before surgery.
    Jira M; Strejcek J; Chodounsky Z; Fuchsova M; Tomasova M; Faltyn J; Suchomelova M
    Arch Geschwulstforsch; 1987; 57(5):379-84. PubMed ID: 3500690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
    Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
    Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
    Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
    Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells.
    Clayman GL; Taylor DL; Liu FJ; Lavedan P; Savage HE; Schantz SP
    Laryngoscope; 1993 Mar; 103(3):299-307. PubMed ID: 7680086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS patients.
    Zerhouni B; Sanhadji K; Kehrli L; Livrozet JM; Touraine JL
    Thymus; 1997; 24(3):147-56. PubMed ID: 9151380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
    Kimoto Y; Taguchi T
    Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.